Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 432

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

A vaccine targeting mutant IDH1 in newly diagnosed glioma

Open access
Platten, Michael, Bunse, Lukas, Wick, Antje, Bunse, Theresa, Le Cornet, Lucian, Harting, Inga, Sahm, Felix, Sanghvi, Khwab, Tan, Chin Leng, Poschke, Isabel, Green, Edward, Justesen, Sune, Behrens, Geoffrey A., Breckwoldt, Michael O., Freitag, Angelika, Rother, Lisa-Marie, Schmitt, Anita, Schnell, Oliver, Hense, Jörg, Misch, Martin, Krex, Dietmar, Stevanovic, Stefan, Tabatabai, Ghazaleh, Steinbach, Joachim P., Bendszus, Martin, von Deimling, Andreas, Schmitt, Michael, Wick, Wolfgang·2021·Nature

Abstract

Mutated isocitrate dehydrogenase 1 (IDH1) defines a molecularly distinct subtype of diffuse glioma 1–3. The most common IDH1 mutation in gliomas affects codon 132 and encodes IDH1(R132H), which harbours a shared clonal neoepitope that is presented on major histocompatibility complex (MHC) class II 4,5. An IDH1(R132H)-specific peptide vaccine (IDH1-vac) induces specific therapeutic T helper cell responses that are effective against IDH1(R132H)+ tumours in syngeneic MHC-humanized mice 4,6–8. Here we describe a multicentre, single-arm, open-label, first-in-humans phase I trial that we carried out in 33 patients with newly diagnosed World Health Organization grade 3 and 4 IDH1(R132H)+ astrocytomas (Neurooncology Working Group of the German Cancer Society trial 16 (NOA16), ClinicalTrials.gov identifier NCT02454634). The trial met its primary safety endpoint, with vaccine-related adverse events restricted to grade 1. Vaccine-induced immune responses were observed in 93.3% of patients across multiple MHC alleles. Three-year progression-free and death-free rates were 0.63 and 0.84, respectively. Patients with immune responses showed a two-year progression-free rate of 0.82. Two patients without an immune response showed tumour progression within two years of first diagnosis. A mutation-specificity score that incorporates the duration and level of vaccine-induced IDH1(R132H)-specific T cell responses was associated with intratumoral presentation of the IDH1(R132H) neoantigen in pre-treatment tumour tissue. There was a high frequency of pseudoprogression, which indicates intratumoral inflammatory reactions. Pseudoprogression was associated with increased vaccine-induced peripheral T cell responses. Combined single-cell RNA and T cell receptor sequencing showed that tumour-infiltrating CD40LG+ and CXCL13+ T helper cell clusters in a patient with pseudoprogression were dominated by a single IDH1(R132H)-reactive T cell receptor.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41586-021-03363-z

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

See all 432

Metadata

Authors
Platten, M., Bunse, L., Wick, A., Bunse, T., Le Cornet, L., Harting, I., Sahm, F., Sanghvi, K., Tan, C. L., Poschke, I., Green, E., Justesen, S., Behrens, G. A., Breckwoldt, M. O., Freitag, A., Rother, L.-M., Schmitt, A., Schnell, O., Hense, J., Misch, M., Krex, D., Stevanovic, S., Tabatabai, G., Steinbach, J. P., Bendszus, M., von Deimling, A., Schmitt, M., & Wick, W.
Venue
Nature
Published
2021-03-24
Volume
592
Issue
7854
Pages
463-468
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W3137406939
Cited by
432
References
28
FWCI
33.14
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A vaccine targeting mutant IDH1 in newly diagnosed glioma. https://app.cochat.ai/papers/10.1038/s41586-021-03363-z
The paper
Platten, M., Bunse, L., Wick, A., Bunse, T., Le Cornet, L., Harting, I., Sahm, F., Sanghvi, K., Tan, C. L., Poschke, I., Green, E., Justesen, S., Behrens, G. A., Breckwoldt, M. O., Freitag, A., Rother, L.-M., Schmitt, A., Schnell, O., Hense, J., . . . Wick, W. (2021). A vaccine targeting mutant IDH1 in newly diagnosed glioma. Nature. https://doi.org/10.1038/s41586-021-03363-z

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.